nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—CHRM5—Tiotropium—chronic obstructive pulmonary disease	0.196	0.254	CbGbCtD
Darifenacin—CHRM3—Tiotropium—chronic obstructive pulmonary disease	0.125	0.162	CbGbCtD
Darifenacin—CHRM1—Tiotropium—chronic obstructive pulmonary disease	0.109	0.141	CbGbCtD
Darifenacin—CHRM2—Tiotropium—chronic obstructive pulmonary disease	0.1	0.13	CbGbCtD
Darifenacin—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0411	0.0532	CbGbCtD
Darifenacin—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0411	0.0532	CbGbCtD
Darifenacin—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0366	0.0474	CbGbCtD
Darifenacin—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0345	0.0447	CbGbCtD
Darifenacin—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0233	0.0302	CbGbCtD
Darifenacin—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0222	0.0288	CbGbCtD
Darifenacin—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0198	0.0257	CbGbCtD
Darifenacin—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0116	0.0151	CbGbCtD
Darifenacin—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.011	0.0142	CbGbCtD
Darifenacin—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00054	0.0028	CcSEcCtD
Darifenacin—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00054	0.00279	CcSEcCtD
Darifenacin—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000539	0.00279	CcSEcCtD
Darifenacin—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000537	0.00278	CcSEcCtD
Darifenacin—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000536	0.00278	CcSEcCtD
Darifenacin—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000536	0.00278	CcSEcCtD
Darifenacin—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000535	0.00277	CcSEcCtD
Darifenacin—Shock—Tiotropium—chronic obstructive pulmonary disease	0.00053	0.00274	CcSEcCtD
Darifenacin—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000528	0.00274	CcSEcCtD
Darifenacin—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000526	0.00272	CcSEcCtD
Darifenacin—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000525	0.00272	CcSEcCtD
Darifenacin—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000524	0.00271	CcSEcCtD
Darifenacin—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000523	0.00271	CcSEcCtD
Darifenacin—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.000522	0.0027	CcSEcCtD
Darifenacin—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.000522	0.0027	CcSEcCtD
Darifenacin—Injury—Prednisolone—chronic obstructive pulmonary disease	0.000521	0.0027	CcSEcCtD
Darifenacin—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000521	0.0027	CcSEcCtD
Darifenacin—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000517	0.00268	CcSEcCtD
Darifenacin—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000515	0.00267	CcSEcCtD
Darifenacin—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000515	0.00267	CcSEcCtD
Darifenacin—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000509	0.00264	CcSEcCtD
Darifenacin—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000506	0.00262	CcSEcCtD
Darifenacin—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.000506	0.00262	CcSEcCtD
Darifenacin—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000503	0.0026	CcSEcCtD
Darifenacin—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000496	0.00257	CcSEcCtD
Darifenacin—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000493	0.00255	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000491	0.00254	CcSEcCtD
Darifenacin—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000487	0.00252	CcSEcCtD
Darifenacin—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000487	0.00252	CcSEcCtD
Darifenacin—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000487	0.00252	CcSEcCtD
Darifenacin—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000487	0.00252	CcSEcCtD
Darifenacin—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000477	0.00247	CcSEcCtD
Darifenacin—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000474	0.00246	CcSEcCtD
Darifenacin—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000471	0.00244	CcSEcCtD
Darifenacin—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000471	0.00244	CcSEcCtD
Darifenacin—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000467	0.00242	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000465	0.00241	CcSEcCtD
Darifenacin—Cough—Formoterol—chronic obstructive pulmonary disease	0.000465	0.00241	CcSEcCtD
Darifenacin—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000465	0.00241	CcSEcCtD
Darifenacin—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000461	0.00239	CcSEcCtD
Darifenacin—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000461	0.00239	CcSEcCtD
Darifenacin—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.00046	0.00238	CcSEcCtD
Darifenacin—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.00046	0.00238	CcSEcCtD
Darifenacin—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00046	0.00238	CcSEcCtD
Darifenacin—Cough—Montelukast—chronic obstructive pulmonary disease	0.000455	0.00236	CcSEcCtD
Darifenacin—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000454	0.00235	CcSEcCtD
Darifenacin—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000454	0.00235	CcSEcCtD
Darifenacin—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000452	0.00234	CcSEcCtD
Darifenacin—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000451	0.00234	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000451	0.00233	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000451	0.00233	CcSEcCtD
Darifenacin—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000445	0.0023	CcSEcCtD
Darifenacin—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000444	0.0023	CcSEcCtD
Darifenacin—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000444	0.0023	CcSEcCtD
Darifenacin—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000444	0.0023	CcSEcCtD
Darifenacin—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000442	0.00229	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000441	0.00228	CcSEcCtD
Darifenacin—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000441	0.00228	CcSEcCtD
Darifenacin—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000439	0.00227	CcSEcCtD
Darifenacin—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000439	0.00227	CcSEcCtD
Darifenacin—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000435	0.00225	CcSEcCtD
Darifenacin—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000435	0.00225	CcSEcCtD
Darifenacin—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000435	0.00225	CcSEcCtD
Darifenacin—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000435	0.00225	CcSEcCtD
Darifenacin—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000434	0.00225	CcSEcCtD
Darifenacin—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000432	0.00224	CcSEcCtD
Darifenacin—Infection—Formoterol—chronic obstructive pulmonary disease	0.000432	0.00224	CcSEcCtD
Darifenacin—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000428	0.00222	CcSEcCtD
Darifenacin—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000426	0.00221	CcSEcCtD
Darifenacin—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000426	0.00221	CcSEcCtD
Darifenacin—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000426	0.00221	CcSEcCtD
Darifenacin—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000426	0.00221	CcSEcCtD
Darifenacin—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000426	0.00221	CcSEcCtD
Darifenacin—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000424	0.0022	CcSEcCtD
Darifenacin—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000424	0.0022	CcSEcCtD
Darifenacin—Infection—Montelukast—chronic obstructive pulmonary disease	0.000423	0.00219	CcSEcCtD
Darifenacin—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000422	0.00219	CcSEcCtD
Darifenacin—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000422	0.00219	CcSEcCtD
Darifenacin—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000421	0.00218	CcSEcCtD
Darifenacin—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000419	0.00217	CcSEcCtD
Darifenacin—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000418	0.00216	CcSEcCtD
Darifenacin—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000414	0.00214	CcSEcCtD
Darifenacin—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000411	0.00213	CcSEcCtD
Darifenacin—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000411	0.00213	CcSEcCtD
Darifenacin—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000408	0.00211	CcSEcCtD
Darifenacin—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000404	0.00209	CcSEcCtD
Darifenacin—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000404	0.00209	CcSEcCtD
Darifenacin—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000403	0.00208	CcSEcCtD
Darifenacin—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000401	0.00207	CcSEcCtD
Darifenacin—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000399	0.00207	CcSEcCtD
Darifenacin—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000397	0.00206	CcSEcCtD
Darifenacin—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000397	0.00206	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000396	0.00205	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000396	0.00205	CcSEcCtD
Darifenacin—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000393	0.00204	CcSEcCtD
Darifenacin—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000393	0.00204	CcSEcCtD
Darifenacin—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000391	0.00202	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000388	0.00201	CcSEcCtD
Darifenacin—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000388	0.00201	CcSEcCtD
Darifenacin—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000388	0.00201	CcSEcCtD
Darifenacin—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000387	0.002	CcSEcCtD
Darifenacin—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000387	0.002	CcSEcCtD
Darifenacin—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000385	0.00199	CcSEcCtD
Darifenacin—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000383	0.00198	CcSEcCtD
Darifenacin—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000383	0.00198	CcSEcCtD
Darifenacin—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000381	0.00197	CcSEcCtD
Darifenacin—Injury—Prednisone—chronic obstructive pulmonary disease	0.000379	0.00196	CcSEcCtD
Darifenacin—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000379	0.00196	CcSEcCtD
Darifenacin—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000378	0.00196	CcSEcCtD
Darifenacin—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000377	0.00195	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000375	0.00194	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000375	0.00194	CcSEcCtD
Darifenacin—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000375	0.00194	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000374	0.00194	CcSEcCtD
Darifenacin—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000372	0.00193	CcSEcCtD
Darifenacin—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000372	0.00193	CcSEcCtD
Darifenacin—Pain—Formoterol—chronic obstructive pulmonary disease	0.000372	0.00193	CcSEcCtD
Darifenacin—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000372	0.00193	CcSEcCtD
Darifenacin—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000371	0.00192	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000368	0.0019	CcSEcCtD
Darifenacin—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000366	0.0019	CcSEcCtD
Darifenacin—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000365	0.00189	CcSEcCtD
Darifenacin—Pain—Montelukast—chronic obstructive pulmonary disease	0.000364	0.00189	CcSEcCtD
Darifenacin—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000363	0.00188	CcSEcCtD
Darifenacin—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000361	0.00187	CcSEcCtD
Darifenacin—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00036	0.00187	CcSEcCtD
Darifenacin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00036	0.00186	CcSEcCtD
Darifenacin—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000358	0.00186	CcSEcCtD
Darifenacin—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000358	0.00186	CcSEcCtD
Darifenacin—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000358	0.00185	CcSEcCtD
Darifenacin—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000356	0.00184	CcSEcCtD
Darifenacin—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000356	0.00184	CcSEcCtD
Darifenacin—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000356	0.00184	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000355	0.00184	CcSEcCtD
Darifenacin—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000351	0.00182	CcSEcCtD
Darifenacin—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000351	0.00182	CcSEcCtD
Darifenacin—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000348	0.0018	CcSEcCtD
Darifenacin—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000344	0.00178	CcSEcCtD
Darifenacin—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000344	0.00178	CcSEcCtD
Darifenacin—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000343	0.00177	CcSEcCtD
Darifenacin—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00034	0.00176	CcSEcCtD
Darifenacin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000339	0.00176	CcSEcCtD
Darifenacin—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000339	0.00176	CcSEcCtD
Darifenacin—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000338	0.00175	CcSEcCtD
Darifenacin—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000338	0.00175	CcSEcCtD
Darifenacin—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000337	0.00174	CcSEcCtD
Darifenacin—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000336	0.00174	CcSEcCtD
Darifenacin—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000336	0.00174	CcSEcCtD
Darifenacin—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000325	0.00168	CcSEcCtD
Darifenacin—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00032	0.00166	CcSEcCtD
Darifenacin—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00032	0.00166	CcSEcCtD
Darifenacin—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00032	0.00166	CcSEcCtD
Darifenacin—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000319	0.00165	CcSEcCtD
Darifenacin—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000319	0.00165	CcSEcCtD
Darifenacin—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000314	0.00162	CcSEcCtD
Darifenacin—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000312	0.00162	CcSEcCtD
Darifenacin—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000312	0.00162	CcSEcCtD
Darifenacin—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000308	0.00159	CcSEcCtD
Darifenacin—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000308	0.00159	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000307	0.00159	CcSEcCtD
Darifenacin—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000306	0.00158	CcSEcCtD
Darifenacin—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000303	0.00157	CcSEcCtD
Darifenacin—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000301	0.00156	CcSEcCtD
Darifenacin—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000298	0.00154	CcSEcCtD
Darifenacin—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000298	0.00154	CcSEcCtD
Darifenacin—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000295	0.00153	CcSEcCtD
Darifenacin—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000291	0.00151	CcSEcCtD
Darifenacin—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000291	0.0015	CcSEcCtD
Darifenacin—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000288	0.00149	CcSEcCtD
Darifenacin—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.00149	CcSEcCtD
Darifenacin—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000282	0.00146	CcSEcCtD
Darifenacin—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000281	0.00145	CcSEcCtD
Darifenacin—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000277	0.00144	CcSEcCtD
Darifenacin—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000276	0.00143	CcSEcCtD
Darifenacin—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.00143	CcSEcCtD
Darifenacin—Rash—Formoterol—chronic obstructive pulmonary disease	0.000274	0.00142	CcSEcCtD
Darifenacin—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000274	0.00142	CcSEcCtD
Darifenacin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000274	0.00142	CcSEcCtD
Darifenacin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000274	0.00142	CcSEcCtD
Darifenacin—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000274	0.00142	CcSEcCtD
Darifenacin—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000272	0.00141	CcSEcCtD
Darifenacin—Headache—Formoterol—chronic obstructive pulmonary disease	0.000272	0.00141	CcSEcCtD
Darifenacin—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000272	0.00141	CcSEcCtD
Darifenacin—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.00141	CcSEcCtD
Darifenacin—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000271	0.0014	CcSEcCtD
Darifenacin—Rash—Montelukast—chronic obstructive pulmonary disease	0.000269	0.00139	CcSEcCtD
Darifenacin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000268	0.00139	CcSEcCtD
Darifenacin—Headache—Montelukast—chronic obstructive pulmonary disease	0.000267	0.00138	CcSEcCtD
Darifenacin—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000264	0.00137	CcSEcCtD
Darifenacin—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00135	CcSEcCtD
Darifenacin—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.00134	CcSEcCtD
Darifenacin—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000259	0.00134	CcSEcCtD
Darifenacin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.00134	CcSEcCtD
Darifenacin—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000258	0.00134	CcSEcCtD
Darifenacin—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000258	0.00134	CcSEcCtD
Darifenacin—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000257	0.00133	CcSEcCtD
Darifenacin—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000254	0.00131	CcSEcCtD
Darifenacin—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000253	0.00131	CcSEcCtD
Darifenacin—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000249	0.00129	CcSEcCtD
Darifenacin—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000244	0.00126	CcSEcCtD
Darifenacin—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.00024	0.00124	CcSEcCtD
Darifenacin—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000236	0.00122	CcSEcCtD
Darifenacin—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000236	0.00122	CcSEcCtD
Darifenacin—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000232	0.0012	CcSEcCtD
Darifenacin—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.00023	0.00119	CcSEcCtD
Darifenacin—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000228	0.00118	CcSEcCtD
Darifenacin—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000225	0.00117	CcSEcCtD
Darifenacin—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000219	0.00113	CcSEcCtD
Darifenacin—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000213	0.0011	CcSEcCtD
Darifenacin—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000211	0.00109	CcSEcCtD
Darifenacin—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000201	0.00104	CcSEcCtD
Darifenacin—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000198	0.00102	CcSEcCtD
Darifenacin—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000194	0.001	CcSEcCtD
Darifenacin—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000192	0.000992	CcSEcCtD
Darifenacin—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000188	0.000974	CcSEcCtD
Darifenacin—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000184	0.000954	CcSEcCtD
Darifenacin—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000181	0.000937	CcSEcCtD
Darifenacin—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000179	0.000924	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000177	0.000918	CcSEcCtD
Darifenacin—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000174	0.000898	CcSEcCtD
Darifenacin—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000171	0.000886	CcSEcCtD
Darifenacin—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000171	0.000886	CcSEcCtD
Darifenacin—Infection—Prednisone—chronic obstructive pulmonary disease	0.00017	0.00088	CcSEcCtD
Darifenacin—Shock—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000872	CcSEcCtD
Darifenacin—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000869	CcSEcCtD
Darifenacin—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000167	0.000865	CcSEcCtD
Darifenacin—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000861	CcSEcCtD
Darifenacin—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000165	0.000857	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000807	CcSEcCtD
Darifenacin—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.000806	CcSEcCtD
Darifenacin—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000155	0.000801	CcSEcCtD
Darifenacin—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000151	0.00078	CcSEcCtD
Darifenacin—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000769	CcSEcCtD
Darifenacin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000768	CcSEcCtD
Darifenacin—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000764	CcSEcCtD
Darifenacin—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000146	0.000758	CcSEcCtD
Darifenacin—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000141	0.00073	CcSEcCtD
Darifenacin—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000725	CcSEcCtD
Darifenacin—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.00014	0.000724	CcSEcCtD
Darifenacin—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000135	0.0007	CcSEcCtD
Darifenacin—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000653	CcSEcCtD
Darifenacin—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000636	CcSEcCtD
Darifenacin—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000627	CcSEcCtD
Darifenacin—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000606	CcSEcCtD
Darifenacin—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000586	CcSEcCtD
Darifenacin—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000563	CcSEcCtD
Darifenacin—Rash—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000559	CcSEcCtD
Darifenacin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000558	CcSEcCtD
Darifenacin—Headache—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000555	CcSEcCtD
Darifenacin—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000526	CcSEcCtD
Darifenacin—CHRM5—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.2e-05	0.00149	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5.18e-05	0.00148	CbGpPWpGaD
Darifenacin—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.17e-05	0.00148	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5.16e-05	0.00148	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.14e-05	0.00147	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5.11e-05	0.00146	CbGpPWpGaD
Darifenacin—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.1e-05	0.00146	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	5.06e-05	0.00145	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	4.94e-05	0.00142	CbGpPWpGaD
Darifenacin—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.9e-05	0.0014	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	4.86e-05	0.00139	CbGpPWpGaD
Darifenacin—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.83e-05	0.00138	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	4.76e-05	0.00136	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	4.74e-05	0.00136	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	4.7e-05	0.00135	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	4.69e-05	0.00134	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	4.69e-05	0.00134	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	4.64e-05	0.00133	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	4.63e-05	0.00133	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	4.62e-05	0.00132	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	4.57e-05	0.00131	CbGpPWpGaD
Darifenacin—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.41e-05	0.00126	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.37e-05	0.00125	CbGpPWpGaD
Darifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.36e-05	0.00125	CbGpPWpGaD
Darifenacin—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.35e-05	0.00125	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GC—chronic obstructive pulmonary disease	4.25e-05	0.00122	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.17e-05	0.00119	CbGpPWpGaD
Darifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.17e-05	0.00119	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.16e-05	0.00119	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.14e-05	0.00119	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.13e-05	0.00118	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.12e-05	0.00118	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.12e-05	0.00118	CbGpPWpGaD
Darifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	4.12e-05	0.00118	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	4.11e-05	0.00118	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.09e-05	0.00117	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.95e-05	0.00113	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.94e-05	0.00113	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.94e-05	0.00113	CbGpPWpGaD
Darifenacin—CHRM1—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	3.89e-05	0.00111	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.88e-05	0.00111	CbGpPWpGaD
Darifenacin—CHRM3—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	3.88e-05	0.00111	CbGpPWpGaD
Darifenacin—CHRM2—Regulation of Actin Cytoskeleton—EGFR—chronic obstructive pulmonary disease	3.84e-05	0.0011	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.79e-05	0.00108	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.78e-05	0.00108	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.74e-05	0.00107	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.72e-05	0.00106	CbGpPWpGaD
Darifenacin—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.68e-05	0.00105	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.66e-05	0.00105	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.65e-05	0.00105	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	3.65e-05	0.00104	CbGpPWpGaD
Darifenacin—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.63e-05	0.00104	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.62e-05	0.00104	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.62e-05	0.00104	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.61e-05	0.00103	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.57e-05	0.00102	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.53e-05	0.00101	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.52e-05	0.00101	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.47e-05	0.000993	CbGpPWpGaD
Darifenacin—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.38e-05	0.000968	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.38e-05	0.000967	CbGpPWpGaD
Darifenacin—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.33e-05	0.000955	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.32e-05	0.000951	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.32e-05	0.000951	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.32e-05	0.00095	CbGpPWpGaD
Darifenacin—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.2e-05	0.000918	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.18e-05	0.00091	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.18e-05	0.00091	CbGpPWpGaD
Darifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	3.17e-05	0.000906	CbGpPWpGaD
Darifenacin—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.16e-05	0.000905	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.15e-05	0.000902	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.03e-05	0.000869	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.02e-05	0.000864	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.94e-05	0.000841	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.93e-05	0.000838	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.91e-05	0.000832	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.9e-05	0.00083	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.9e-05	0.00083	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.89e-05	0.000828	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.84e-05	0.000814	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.78e-05	0.000795	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.77e-05	0.000793	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.76e-05	0.000789	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.74e-05	0.000785	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.64e-05	0.000756	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.62e-05	0.00075	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.61e-05	0.000748	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.61e-05	0.000747	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.58e-05	0.00074	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.58e-05	0.000738	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.57e-05	0.000736	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.54e-05	0.000728	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.43e-05	0.000695	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.38e-05	0.000681	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.37e-05	0.000678	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.36e-05	0.000676	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.35e-05	0.000673	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.35e-05	0.000672	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.34e-05	0.00067	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.33e-05	0.000668	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.32e-05	0.000666	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.32e-05	0.000665	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.31e-05	0.000661	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GCLC—chronic obstructive pulmonary disease	2.29e-05	0.000657	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.26e-05	0.000646	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.24e-05	0.000641	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.24e-05	0.000641	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.23e-05	0.000639	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.23e-05	0.000639	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2.23e-05	0.000638	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2.22e-05	0.000636	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.21e-05	0.000633	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.21e-05	0.000632	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.16e-05	0.000619	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.12e-05	0.000608	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.12e-05	0.000606	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.1e-05	0.0006	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CTGF—chronic obstructive pulmonary disease	2.09e-05	0.0006	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.08e-05	0.000596	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.05e-05	0.000586	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.04e-05	0.000584	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.02e-05	0.000578	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.99e-05	0.000571	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.93e-05	0.000552	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.87e-05	0.000537	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.86e-05	0.000533	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.86e-05	0.000532	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.85e-05	0.00053	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.83e-05	0.000525	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.8e-05	0.000514	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.78e-05	0.00051	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.71e-05	0.000489	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.7e-05	0.000488	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.69e-05	0.000484	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.66e-05	0.000476	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.64e-05	0.000469	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.63e-05	0.000467	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.63e-05	0.000467	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.63e-05	0.000466	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.62e-05	0.000464	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.62e-05	0.000463	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.61e-05	0.000461	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.59e-05	0.000454	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.56e-05	0.000446	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.54e-05	0.000442	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.52e-05	0.000436	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.52e-05	0.000434	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.51e-05	0.000433	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.5e-05	0.00043	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.48e-05	0.000423	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.45e-05	0.000415	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.4e-05	0.000402	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.4e-05	0.000401	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.4e-05	0.000401	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.39e-05	0.000397	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.39e-05	0.000397	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.37e-05	0.000393	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.26e-05	0.000362	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.26e-05	0.000361	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.25e-05	0.000359	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.25e-05	0.000359	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.25e-05	0.000358	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.25e-05	0.000357	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.24e-05	0.000356	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.24e-05	0.000355	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.19e-05	0.000341	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.19e-05	0.00034	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.15e-05	0.00033	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.15e-05	0.000329	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.14e-05	0.000328	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.14e-05	0.000327	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.14e-05	0.000326	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.14e-05	0.000326	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.13e-05	0.000325	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.13e-05	0.000324	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.13e-05	0.000322	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.1e-05	0.000314	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.09e-05	0.000313	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.09e-05	0.000311	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.08e-05	0.00031	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.02e-05	0.000292	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.02e-05	0.000291	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.01e-05	0.000288	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.01e-05	0.000288	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.63e-06	0.000276	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.62e-06	0.000275	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.56e-06	0.000274	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ALB—chronic obstructive pulmonary disease	9.53e-06	0.000273	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.49e-06	0.000272	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.16e-06	0.000262	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—NOS3—chronic obstructive pulmonary disease	9.11e-06	0.000261	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.1e-06	0.00026	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.08e-06	0.00026	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	8.97e-06	0.000257	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.84e-06	0.000253	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.71e-06	0.000249	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.39e-06	0.00024	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.38e-06	0.00024	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.36e-06	0.00024	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.28e-06	0.000237	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	8.19e-06	0.000234	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.17e-06	0.000234	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.01e-06	0.000229	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.98e-06	0.000229	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.91e-06	0.000226	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.82e-06	0.000224	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.65e-06	0.000219	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.62e-06	0.000218	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.55e-06	0.000216	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.54e-06	0.000216	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.5e-06	0.000215	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.35e-06	0.00021	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.18e-06	0.000206	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.04e-06	0.000202	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.78e-06	0.000194	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.76e-06	0.000194	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.69e-06	0.000192	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.45e-06	0.000185	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.43e-06	0.000184	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.37e-06	0.000182	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.29e-06	0.00018	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.2e-06	0.000178	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.17e-06	0.000177	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.13e-06	0.000176	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.11e-06	0.000175	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.06e-06	0.000173	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.91e-06	0.000169	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.78e-06	0.000166	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	5.7e-06	0.000163	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.65e-06	0.000162	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.51e-06	0.000158	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.49e-06	0.000157	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.48e-06	0.000157	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	5.45e-06	0.000156	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.44e-06	0.000156	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.41e-06	0.000155	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.06e-06	0.000145	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.04e-06	0.000144	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.99e-06	0.000143	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.96e-06	0.000142	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.94e-06	0.000141	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.89e-06	0.00014	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.16e-06	0.000119	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.15e-06	0.000119	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.11e-06	0.000118	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.81e-06	0.000109	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.8e-06	0.000109	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.76e-06	0.000108	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.73e-06	0.000107	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.56e-06	0.000102	CbGpPWpGaD
